Source: University of Texas M. D. Anderson Cancer Center
Date: December 28, 2006
Summary:
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
No comments:
Post a Comment